The short version
14 companies supply this market — deep enough that no single failure threatens the supply. The price has fallen 66% in a year, to $1.29 per mL — and generics that get this cheap tend to get abandoned rather than defended. It is in shortage right now. One of its named manufacturing plants, Somerset Therapeutics Private Limited, failed FDA inspectionwithin the last two years — the agency’s most serious outcome. Put together: this is a fragile supply — if anything else goes wrong, there is very little slack to absorb it.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.